<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123278</url>
  </required_header>
  <id_info>
    <org_study_id>TestoMet05</org_study_id>
    <nct_id>NCT01123278</nct_id>
  </id_info>
  <brief_title>Testosterone Replacement in Metabolic Syndrome and Inflammation</brief_title>
  <acronym>TERMSINFAT</acronym>
  <official_title>Testosterone Replacement in Metabolic Syndrome and Inflammation of Fat Tissue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypogonadism (HG) frequently complicates the Metabolic Syndrome (MetS), whether testosterone
      replacement (TRT) is beneficial has not been clearly ascertained. This study was designed to
      address the effects of TRT on insulin resistance, body composition and pro-inflammatory
      status in naïve patients with MetS and HG.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The features of Metabolic Syndrome (MetS) include abdominal obesity, atherogenic
      dyslipidemia, raised blood pressure, insulin resistance or glucose intolerance. These
      symptoms are also frequently found in hypogonadal men.

      Adipose tissue and androgens in male obesity are reciprocally linked. Total and free
      testosterone (T) are decreased in proportion to the degree of body fatness while T regulates
      insulin sensitivity and body composition. As a consequence, hypoandrogenism carries an
      additional independent risk for cardiovascular and metabolic disorders. Men with type 2
      diabetes mellitus (T2D) exhibit lowered T levels that are inversely correlated to HbA1c. In
      addition, abdominal adiposity causes an impairment of testicular steroidogenesis that is
      directly linked to circulating adipokines; enhanced cytokine release from
      macrophage-infiltrated adipose tissue is pivotal to the pathogenesis of insulin resistance
      and atherosclerosis. Both MetS and T2D share with hypogonadism such a proinflammatory state.

      For this reason we performed a randomized controlled trial on the effects of TRT on insulin
      resistance and circulating inflammatory markers in a cohort of middle-aged men with mild
      hypogonadism and MetS at first diagnosis, that were not taking medications known to influence
      the investigated outcomes. We established strict criteria for enrollment and used a
      physiological replacing therapy.

      Given that testosterone replacement therapy (TRT) determines a reduction of body fat mass
      paralleled by an increase in fat free mass (6), and that TRT exerts an anti-inflammatory role
      inhibiting interleukins (IL), in particular the IL-6 gene (14), it remains to be established
      whether these independent effects also reflect in an improvement in insulin resistance.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fat-Free Mass (kg)</measure>
    <time_frame>3 months</time_frame>
    <description>Estimate of within subject absolute change in fat-free mass measured by DEXA (dual energy x-ray absorptiometry) at 3 months (90 days) interval during active or placebo treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fat Mass (kg)</measure>
    <time_frame>3 months</time_frame>
    <description>Estimate of within subject absolute change (Kg) in fat mass measured by DEXA at 3 months (90 days) interval during active or placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR (homeostasis model assessment)- (insulin resistance)</measure>
    <time_frame>3 months</time_frame>
    <description>Estimate of within subject absolute change in measure of insulin resistance homeostatic model HOMA-IR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP (C reactive protein)</measure>
    <time_frame>3 months</time_frame>
    <description>C reactive protein (High sensitivity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukins</measure>
    <time_frame>3 months</time_frame>
    <description>Within subject absolute and percentage change in serum:
IL-1, IL-6, IL-10, IL-12, IL-2, IL-8, TNFa (tumor necrosis factor alpha)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokines</measure>
    <time_frame>3 months</time_frame>
    <description>Estimate of within subject absolute change in serum:
ADIPONECTIN, LEPTIN, RESISTIN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>3 months</time_frame>
    <description>Waist circumference (cm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IIEF</measure>
    <time_frame>3 months</time_frame>
    <description>International Index of Erectile Dysfunction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penile CDU (color Doppler ultrasound)</measure>
    <time_frame>3 months</time_frame>
    <description>Penile Color-Doppler Ultrasonography of cavernosal arteries before and after active or placebo treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSA (prostatic specific antigen)</measure>
    <time_frame>3 months</time_frame>
    <description>PSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hb, Htc</measure>
    <time_frame>3 months</time_frame>
    <description>haemoglobin and haematocrit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat-free mass</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukins</measure>
    <time_frame>6 months</time_frame>
    <description>Serum IL-1, IL-6, IL-10, IL-12, IL-2, IL-8, TNFa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipokines</measure>
    <time_frame>6 months</time_frame>
    <description>Serum ADIPONECTIN, LEPTIN, RESISTIN.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hypogonadism</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Obesity</condition>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Testosterone gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone transdermal gel 50 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone</intervention_name>
    <description>Testosterone transdermal gel 50 mg/day (5 gr)</description>
    <arm_group_label>Testosterone gel</arm_group_label>
    <other_name>Androgel</other_name>
    <other_name>Testogel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo transdermal gel (5 gr)</description>
    <arm_group_label>Placebo gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Metabolic Syndrome according to ATPIII

          -  patients with mild hypogonadism (both testosterone evaluations between 6 and 11
             nmol/L)

          -  patients naïve to hypoglycemic therapies

        Exclusion Criteria:

          -  patients on hypoglycemic medications

          -  patients with severe hypogonadism (&lt;5 nmol/L)

          -  patients with borderline T values hypogonadism (&gt;11 nmol/L)

          -  patients with contraindication to testosterone therapy: prostate cancer, PSA&gt;4 ng/ml,
             severe hepatic or renal insufficiency, Hb&gt;17, Htc&gt;52%, severe urinary retention
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincenzo Bonifacio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea M Isidori, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Lenzi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dipartimento di Fisiopatologia Medica - Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Hospital - Sapienza University</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab. 1999 Oct;84(10):3673-80.</citation>
    <PMID>10523013</PMID>
  </reference>
  <reference>
    <citation>Aversa A, Isidori AM, Greco EA, Giannetta E, Gianfrilli D, Spera E, Fabbri A. Hormonal supplementation and erectile dysfunction. Eur Urol. 2004 May;45(5):535-8. Erratum in: Eur Urol. 2005 Apr;47(4):564.</citation>
    <PMID>15082192</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Giannetta E, Pozza C, Bonifacio V, Isidori A. Androgens, cardiovascular disease and osteoporosis. J Endocrinol Invest. 2005;28(10 Suppl):73-9. Review.</citation>
    <PMID>16550728</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Greco EA, Aversa A. Androgen deficiency and hormone-replacement therapy. BJU Int. 2005 Aug;96(2):212-6. Review.</citation>
    <PMID>16001962</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005 Sep;63(3):280-93. Review.</citation>
    <PMID>16117815</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94. Review.</citation>
    <PMID>16181230</PMID>
  </reference>
  <reference>
    <citation>Isidori AM, Lenzi A. Testosterone replacement therapy: what we know is not yet enough. Mayo Clin Proc. 2007 Jan;82(1):11-3.</citation>
    <PMID>17285780</PMID>
  </reference>
  <reference>
    <citation>Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf). 2003 May;58(5):632-8.</citation>
    <PMID>12699447</PMID>
  </reference>
  <reference>
    <citation>Aversa A, Isidori AM, De Martino MU, Caprio M, Fabbrini E, Rocchietti-March M, Frajese G, Fabbri A. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf). 2000 Oct;53(4):517-22.</citation>
    <PMID>11012578</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>October 25, 2014</last_update_submitted>
  <last_update_submitted_qc>October 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Roma La Sapienza</investigator_affiliation>
    <investigator_full_name>Andrea M. Isidori</investigator_full_name>
    <investigator_title>Professor of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Adiponectin</keyword>
  <keyword>Resistin</keyword>
  <keyword>Adipocytes</keyword>
  <keyword>Testosterone</keyword>
  <keyword>Aging</keyword>
  <keyword>HOMA-IR</keyword>
  <keyword>Insulin</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <keyword>Obesity</keyword>
  <keyword>Erectile Dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

